A recent article by Lozano et al. showed, by combining in vitro and clinical data, that two pre-treatment T cell characteristics, activated CD4 Tm cell abundance, and a more clonally diverse TCR repertoire in the peripheral blood were linked to ICI-induced irAEs in patients with metastatic melanoma. The gene discussed is CD4; the disease is metastatic melanoma.